NICKOLAS CULPEPPER: Open Payments
NPI 1184069544 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,545 in 133 payments from 16 companies in 2025. Trend: 2023 $837 · 2024 $1,292 · 2025 $2,545
Food & beverage: $2,545
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $410 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $342 |
| Vanda Pharmaceuticals Inc. | 18 | $265 |
| Tris Pharma Inc | 8 | $241 |
| Otsuka America Pharmaceutical, Inc. | 12 | $215 |
| Teva Pharmaceuticals USA, Inc. | 7 | $157 |
| Alkermes, Inc. | 6 | $152 |
| Janssen Pharmaceuticals, Inc | 7 | $141 |
| Collegium Pharmaceutical, Inc. | 11 | $139 |
| E.R. Squibb & Sons, L.L.C. | 5 | $134 |
Products named: VRAYLAR, CAPLYTA, FANAPT, AUSTEDO XR, ARISTADA, Jornay PM, COBENFY, REXULTI.
Industry payments across NV — which companies pay providers there.
